Core--Tissue procurement

核心--组织采购

• 批准号: 6504978
• 负责人: ANDRES J KLEIN-SZANTO
• 金额: $ 16.54万
• 依托单位: FOX CHASE CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-26 至 2002-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6504978
• 关键词: biomedical facility; cancer registry /resource; ovary neoplasms; tissue resource /registry

DESCRIPTION: (Applicant's Description) This core is intended to be a resource for the SPORE as a whole and a valuable source of biological materials for the present and future projects and pilot studies. The laboratory core will be responsible for the collection, storage, and distribution of ovarian tissues and tumors. Fresh/frozen samples will be collected at FCCC and other participating sites and forwarded to our core laboratory. This laboratory core will also be responsible for the collection of archival ovarian tumor specimens and the extraction of DNA to be distributed to the participating projects and pilot studies. It is estimated that more than 400 new ovarian cancers cases will be identified each year through the OCCN (see Core 1) during the course of our proposal. It is very conservatively estimated that approximately 30 percent of these cases will be accrued as fresh/frozen specimens. Paraffin embedded tumors will be available from all cases. Tumor samples will be used by Projects 1, 2, 3 and 5. In addition, we will collect ovaries removed for prophylaxis from women considered to be at increased risk of developing ovarian cancer (e.g., BRCA1, BRCA1 mutant allele carriers, or suggestive family history of cancer) who participate in our chemoprevention trial (see Project 4). These tissues will be processed and distributed for pathology and immunohistochemical evaluation to determine the effect of fenretinide and other chemopreventive agents on the cancer-prone phenotype that we have previously observed in at risk ovaries. By centralizing these services into a core, we will be better able to manage and coordinate the collection, storage, and distribution of a large number of highly valuable tumor, cancer-prone and normal specimens.

产品说明：（申请人的描述）该核心旨在作为整个SPORE的资源以及用于当前和未来项目和试验研究的生物材料的有价值的来源。 实验室核心将负责卵巢组织和肿瘤的收集、储存和分发。 将在FCCC和其他参与研究中心采集新鲜/冷冻样本，并转发至我们的核心实验室。 该实验室核心还将负责收集卵巢肿瘤档案标本和提取DNA，分发给参与项目和试点研究。 据估计，在我们的提案过程中，每年将通过OCCN（见核心1）确定400多例新的卵巢癌病例。 据非常保守的估计，这些病例中约有30%将作为新鲜/冷冻标本累积。 石蜡包埋的肿瘤将从所有病例中获得。 肿瘤样本将用于项目1、2、3和5。 此外，我们将从被认为患卵巢癌风险增加的女性（例如，BRCA 1、BRCA 1突变等位基因携带者或提示性癌症家族史）的患者（见项目4）。 将对这些组织进行处理和分配，用于病理学和免疫组织化学评价，以确定芬维A胺和其他化学预防剂对我们先前在风险卵巢中观察到的癌症易感表型的影响。 通过将这些服务集中到一个核心中，我们将能够更好地管理和协调大量高价值肿瘤、癌症易感和正常标本的收集、储存和分发。